Exact Mass: 874.4053774000001

Exact Mass Matches: 874.4053774000001

Found 69 metabolites which its exact mass value is equals to given mass value 874.4053774000001, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

PGP(a-13:0/6 keto-PGF1alpha)

[(2S)-3-({[(2R)-2-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-3-[(10-methyldodecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C39H72O17P2 (874.4244522)


PGP(a-13:0/6 keto-PGF1alpha) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(a-13:0/6 keto-PGF1alpha), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(6 keto-PGF1alpha/a-13:0)

[(2S)-3-({[(2R)-3-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-2-[(10-methyldodecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C39H72O17P2 (874.4244522)


PGP(6 keto-PGF1alpha/a-13:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(6 keto-PGF1alpha/a-13:0), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(a-13:0/TXB2)

[(2S)-3-({[(2R)-2-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-3-[(10-methyldodecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C39H72O17P2 (874.4244522)


PGP(a-13:0/TXB2) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(a-13:0/TXB2), in particular, consists of one chain of one 10-methyldodecanoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(TXB2/a-13:0)

[(2S)-3-({[(2R)-3-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-2-[(10-methyldodecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C39H72O17P2 (874.4244522)


PGP(TXB2/a-13:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(TXB2/a-13:0), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of 10-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(i-13:0/6 keto-PGF1alpha)

[(2S)-3-({[(2R)-2-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-3-[(11-methyldodecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C39H72O17P2 (874.4244522)


PGP(i-13:0/6 keto-PGF1alpha) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-13:0/6 keto-PGF1alpha), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(6 keto-PGF1alpha/i-13:0)

[(2S)-3-({[(2R)-3-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-2-[(11-methyldodecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C39H72O17P2 (874.4244522)


PGP(6 keto-PGF1alpha/i-13:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(6 keto-PGF1alpha/i-13:0), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(i-13:0/TXB2)

[(2S)-3-({[(2R)-2-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-3-[(11-methyldodecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C39H72O17P2 (874.4244522)


PGP(i-13:0/TXB2) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-13:0/TXB2), in particular, consists of one chain of one 11-methyldodecanoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(TXB2/i-13:0)

[(2S)-3-({[(2R)-3-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-2-[(11-methyldodecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C39H72O17P2 (874.4244522)


PGP(TXB2/i-13:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(TXB2/i-13:0), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of 11-methyldodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   
   
   
   
   
   
   
   

gitoxigenin 3-O-beta-D-glucopyranosyl-(1?3)-beta-D-glucopyranosyl-(1?4)-beta-D-digitalopyranoside

gitoxigenin 3-O-beta-D-glucopyranosyl-(1?3)-beta-D-glucopyranosyl-(1?4)-beta-D-digitalopyranoside

C42H66O19 (874.4198086000001)


   
   

3-O-(2-O-sulfo-beta-D-quinovopyranosyl) quinovic acid 28-betaD-glucopyranosyl ester|3-O-(2-O-sulfo-beta-D-quinovopyranosyl)quinovic acid 28-beta-D-glucopyranosyl ester|3-O--quinovic acid-28-O-ester|3-O-[beta-D-(2-O-sulphonyl)quinovopyranosyl]quinovic acid-28-O-beta-D-glucopyranosyl ester|zygophloside E|zygophyloside E

3-O-(2-O-sulfo-beta-D-quinovopyranosyl) quinovic acid 28-betaD-glucopyranosyl ester|3-O-(2-O-sulfo-beta-D-quinovopyranosyl)quinovic acid 28-beta-D-glucopyranosyl ester|3-O--quinovic acid-28-O-ester|3-O-[beta-D-(2-O-sulphonyl)quinovopyranosyl]quinovic acid-28-O-beta-D-glucopyranosyl ester|zygophloside E|zygophyloside E

C42H66O17S (874.4020506000002)


   

3beta-[O4-(O6-beta-D-Glucopyranosyl-beta-D-glucopyranosyl)-O3-methyl-beta-D-fucopyranosyloxy]-14,16beta-dihydroxy-5beta,14beta-card-20(22)-enolid|3beta-[O4-(O6-beta-D-glucopyranosyl-beta-D-glucopyranosyl)-O3-methyl-beta-D-fucopyranosyloxy]-14,16beta-dihydroxy-5beta,14beta-card-20(22)-enolide|gitoxigenin 3-O-beta-D-glucopyranosyl-(1?6)-beta-D-glucopyranosyl-(1?4)-beta-D-digitalopyranoside|neogitostin

3beta-[O4-(O6-beta-D-Glucopyranosyl-beta-D-glucopyranosyl)-O3-methyl-beta-D-fucopyranosyloxy]-14,16beta-dihydroxy-5beta,14beta-card-20(22)-enolid|3beta-[O4-(O6-beta-D-glucopyranosyl-beta-D-glucopyranosyl)-O3-methyl-beta-D-fucopyranosyloxy]-14,16beta-dihydroxy-5beta,14beta-card-20(22)-enolide|gitoxigenin 3-O-beta-D-glucopyranosyl-(1?6)-beta-D-glucopyranosyl-(1?4)-beta-D-digitalopyranoside|neogitostin

C42H66O19 (874.4198086000001)


   
   

3beta-[O2-(O6-beta-D-glucopyranosyl-beta-D-glucopyranosyl)-O3-methyl-6-deoxy-alpha-L-talopyranosyloxy]-1beta,14-dihydroxy-5beta,14beta-card-20(22)-enolide|3beta-[O2-(O6-beta-D-Glucopyranosyl-beta-D-glucopyranosyl)-O3-methyl-6-desoxy-alpha-L-talopyranosyloxy]-1beta,14-dihydroxy-5beta,14beta-card-20(22)-enolid

3beta-[O2-(O6-beta-D-glucopyranosyl-beta-D-glucopyranosyl)-O3-methyl-6-deoxy-alpha-L-talopyranosyloxy]-1beta,14-dihydroxy-5beta,14beta-card-20(22)-enolide|3beta-[O2-(O6-beta-D-Glucopyranosyl-beta-D-glucopyranosyl)-O3-methyl-6-desoxy-alpha-L-talopyranosyloxy]-1beta,14-dihydroxy-5beta,14beta-card-20(22)-enolid

C42H66O19 (874.4198086000001)


   
   

C42H66O19_7-Hydroxy-8,12-dimethyl-5-oxodihydrospiro[furan-3,5-[6]oxapentacyclo[9.8.0.0~1,7~.0~4,8~.0~12,17~]nonadecan]-15-yl hexopyranosyl-(1->4)hexopyranosyl-(1->4)-6-deoxy-3-O-methylhexopyranoside

NCGC00380855-01_C42H66O19_7-Hydroxy-8,12-dimethyl-5-oxodihydrospiro[furan-3,5-[6]oxapentacyclo[9.8.0.0~1,7~.0~4,8~.0~12,17~]nonadecan]-15-yl hexopyranosyl-(1->4)hexopyranosyl-(1->4)-6-deoxy-3-O-methylhexopyranoside

C42H66O19 (874.4198086000001)


   

C42H66O19_Cardanolide, 18,20-epoxy-3-[[O-hexopyranosyl-(1->4)-O-hexopyranosyl-(1->4)-6-deoxy-3-O-methyl-alpha-L-mannopyranosyl]oxy]-14-hydroxy-, (3beta,8xi,9xi,14xi,17xi,20xi)

NCGC00381292-01_C42H66O19_Cardanolide, 18,20-epoxy-3-[[O-hexopyranosyl-(1->4)-O-hexopyranosyl-(1->4)-6-deoxy-3-O-methyl-alpha-L-mannopyranosyl]oxy]-14-hydroxy-, (3beta,8xi,9xi,14xi,17xi,20xi)-

C42H66O19 (874.4198086000001)


   

15-[(5-{[3,4-dihydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-7-hydroxy-8,12-dimethyl-6-oxaspiro[oxolane-3,5-pentacyclo[9.8.0.0¹,⁷.0⁴,⁸.0¹²,¹⁷]nonadecane]-5-one

15-[(5-{[3,4-dihydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-7-hydroxy-8,12-dimethyl-6-oxaspiro[oxolane-3,5-pentacyclo[9.8.0.0¹,⁷.0⁴,⁸.0¹²,¹⁷]nonadecane]-5-one

C42H66O19 (874.4198086000001)


   

15-[(5-{[3,4-dihydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-7-hydroxy-8,12-dimethyl-6-oxaspiro[oxolane-3,5-pentacyclo[9.8.0.0¹,⁷.0⁴,⁸.0¹²,¹⁷]nonadecane]-5-one_major

15-[(5-{[3,4-dihydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-7-hydroxy-8,12-dimethyl-6-oxaspiro[oxolane-3,5-pentacyclo[9.8.0.0¹,⁷.0⁴,⁸.0¹²,¹⁷]nonadecane]-5-one_major

C42H66O19 (874.4198086000001)


   

15-[(5-{[3,4-dihydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-7-hydroxy-8,12-dimethyl-6-oxaspiro[oxolane-3,5-pentacyclo[9.8.0.0¹,⁷.0⁴,⁸.0¹²,¹⁷]nonadecane]-5-one_3.4\\%

15-[(5-{[3,4-dihydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-7-hydroxy-8,12-dimethyl-6-oxaspiro[oxolane-3,5-pentacyclo[9.8.0.0¹,⁷.0⁴,⁸.0¹²,¹⁷]nonadecane]-5-one_3.4\\%

C42H66O19 (874.4198086000001)


   

15-[(5-{[3,4-dihydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-7-hydroxy-8,12-dimethyl-6-oxaspiro[oxolane-3,5-pentacyclo[9.8.0.0¹,?.0?,?.0¹²,¹?]nonadecane]-5-one

15-[(5-{[3,4-dihydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-7-hydroxy-8,12-dimethyl-6-oxaspiro[oxolane-3,5-pentacyclo[9.8.0.0¹,?.0?,?.0¹²,¹?]nonadecane]-5-one

C42H66O19 (874.4198086000001)


   

(S)-2,2-Bis[bis(4-Methoxy-3,5-diMethylphenyl)phosphino]-4,4,6,6-tetraMethoxybiphenyl

(S)-2,2-Bis[bis(4-Methoxy-3,5-diMethylphenyl)phosphino]-4,4,6,6-tetraMethoxybiphenyl

C52H60O8P2 (874.3763220000001)


   

(R)-2,2-Bis[bis(4-Methoxy-3,5-diMethylphenyl)phosphino]-4,4,6,6-tetraMethoxybiphenyl

(R)-2,2-Bis[bis(4-Methoxy-3,5-diMethylphenyl)phosphino]-4,4,6,6-tetraMethoxybiphenyl

C52H60O8P2 (874.3763220000001)


   

3-[(1R,2S,3S,5Z,7S,8S,10Z,13S,15Z,17R,18R,19R)-3,13,17-tris(2-carboxylatoethyl)-2,7,18-tris(carboxylatomethyl)-1,2,5,7,12,12,15,17-octamethyl-3,8,13,18,19,24-hexahydrocorrin-24-ium-8-yl]propanoate

3-[(1R,2S,3S,5Z,7S,8S,10Z,13S,15Z,17R,18R,19R)-3,13,17-tris(2-carboxylatoethyl)-2,7,18-tris(carboxylatomethyl)-1,2,5,7,12,12,15,17-octamethyl-3,8,13,18,19,24-hexahydrocorrin-24-ium-8-yl]propanoate

C45H54N4O14-6 (874.3636344)


   

3-[(1R,2S,3S,5Z,7S,8S,10Z,13S,15Z,17R,18R,19R)-2,7-bis(2-amino-2-oxoethyl)-3,13,17-tris(2-carboxylatoethyl)-18-(carboxylatomethyl)-1,2,5,7,12,12,15,17-octamethyl-3,8,13,18,19,24-hexahydrocorrin-24-ium-8-yl]propanoate

3-[(1R,2S,3S,5Z,7S,8S,10Z,13S,15Z,17R,18R,19R)-2,7-bis(2-amino-2-oxoethyl)-3,13,17-tris(2-carboxylatoethyl)-18-(carboxylatomethyl)-1,2,5,7,12,12,15,17-octamethyl-3,8,13,18,19,24-hexahydrocorrin-24-ium-8-yl]propanoate

C45H58N6O12-4 (874.4112508000001)


   
   
   
   
   

PGP(a-13:0/6 keto-PGF1alpha)

PGP(a-13:0/6 keto-PGF1alpha)

C39H72O17P2 (874.4244522)


   

PGP(6 keto-PGF1alpha/a-13:0)

PGP(6 keto-PGF1alpha/a-13:0)

C39H72O17P2 (874.4244522)


   

PGP(i-13:0/6 keto-PGF1alpha)

PGP(i-13:0/6 keto-PGF1alpha)

C39H72O17P2 (874.4244522)


   

PGP(6 keto-PGF1alpha/i-13:0)

PGP(6 keto-PGF1alpha/i-13:0)

C39H72O17P2 (874.4244522)


   
   
   
   
   
   
   

Methyllycaconitine citrate

Methyllycaconitine citrate

C43H58N2O17 (874.3735298000001)


Methyllycaconitine citrate is a specific antagonist of α7 neuronal nicotinic acetylcholine receptor (α7nAChR) with blood-brain barrier permeability.

   

4-[3a,5a-dihydroxy-9a-(hydroxymethyl)-7-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-11a-methyl-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

4-[3a,5a-dihydroxy-9a-(hydroxymethyl)-7-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-11a-methyl-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

C42H66O19 (874.4198086000001)


   

4-[(1r,3as,3br,5as,7s,9ar,9bs,11ar)-3a,5a-dihydroxy-9a-(hydroxymethyl)-7-{[(2s,4r,5s,6s)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-11a-methyl-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

4-[(1r,3as,3br,5as,7s,9ar,9bs,11ar)-3a,5a-dihydroxy-9a-(hydroxymethyl)-7-{[(2s,4r,5s,6s)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-11a-methyl-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

C42H66O19 (874.4198086000001)


   

4-{7-[(5-{[3,4-dihydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-2,3a-dihydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl}-5h-furan-2-one

4-{7-[(5-{[3,4-dihydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-2,3a-dihydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl}-5h-furan-2-one

C42H66O19 (874.4198086000001)


   

(1s,2r,4as,6ar,6br,8ar,10s,12ar,12br,14bs)-10-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-methyl-3-(sulfooxy)oxan-2-yl]oxy}-1,2,6b,9,9,12a-hexamethyl-6a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylic acid

(1s,2r,4as,6ar,6br,8ar,10s,12ar,12br,14bs)-10-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-methyl-3-(sulfooxy)oxan-2-yl]oxy}-1,2,6b,9,9,12a-hexamethyl-6a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylic acid

C42H66O17S (874.4020506000002)


   

4-[(1r,2s,3as,3br,5ar,7s,9as,9bs,11ar)-2,3a-dihydroxy-7-{[(3s,4s,5r,6s)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

4-[(1r,2s,3as,3br,5ar,7s,9as,9bs,11ar)-2,3a-dihydroxy-7-{[(3s,4s,5r,6s)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

C42H66O19 (874.4198086000001)


   

2-{n-[(6s)-2,6-diamino-3-[(2s)-2-{[(2s)-2-amino-1-hydroxypropylidene]amino}-3-(3-hydroxyphenyl)-n-methylpropanamido]-5-oxoheptanoyl]-n-{[(2e)-4-hydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-ylidene]methyl}-(c-hydroxycarbonimidoyl)amino}-3-(1h-indol-3-yl)propanoic acid

2-{n-[(6s)-2,6-diamino-3-[(2s)-2-{[(2s)-2-amino-1-hydroxypropylidene]amino}-3-(3-hydroxyphenyl)-n-methylpropanamido]-5-oxoheptanoyl]-n-{[(2e)-4-hydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-ylidene]methyl}-(c-hydroxycarbonimidoyl)amino}-3-(1h-indol-3-yl)propanoic acid

C41H50N10O12 (874.36095)


   

4-[(1r,2s,3as,3br,5ar,7s,9as,9bs,11ar)-7-{[(2r,3r,4r,5s,6r)-5-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-2,3a-dihydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

4-[(1r,2s,3as,3br,5ar,7s,9as,9bs,11ar)-7-{[(2r,3r,4r,5s,6r)-5-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-2,3a-dihydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

C42H66O19 (874.4198086000001)


   

4-[(1r,2s,3as,3br,5ar,7s,9as,9bs,11ar)-2,3a-dihydroxy-7-{[(2r,3r,4r,5s,6r)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

4-[(1r,2s,3as,3br,5ar,7s,9as,9bs,11ar)-2,3a-dihydroxy-7-{[(2r,3r,4r,5s,6r)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

C42H66O19 (874.4198086000001)


   

(2s)-2-({[(1s)-1-{[(1s,2s)-2-[(2s)-2-{[(2s)-2-amino-1-hydroxypropylidene]amino}-3-(3-hydroxyphenyl)-n-methylpropanamido]-1-({[(2z,4r,5r)-4-hydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-ylidene]methyl}-c-hydroxycarbonimidoyl)propyl]-c-hydroxycarbonimidoyl}ethyl]-c-hydroxycarbonimidoyl}amino)-3-(1h-indol-3-yl)propanoic acid

(2s)-2-({[(1s)-1-{[(1s,2s)-2-[(2s)-2-{[(2s)-2-amino-1-hydroxypropylidene]amino}-3-(3-hydroxyphenyl)-n-methylpropanamido]-1-({[(2z,4r,5r)-4-hydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-ylidene]methyl}-c-hydroxycarbonimidoyl)propyl]-c-hydroxycarbonimidoyl}ethyl]-c-hydroxycarbonimidoyl}amino)-3-(1h-indol-3-yl)propanoic acid

C41H50N10O12 (874.36095)


   

[30-oxo-16-(sulfooxy)-2-[2-(sulfooxy)undec-9-en-1-yl]-1-oxacyclotriacont-28-en-14-yl]oxidanesulfonic acid

[30-oxo-16-(sulfooxy)-2-[2-(sulfooxy)undec-9-en-1-yl]-1-oxacyclotriacont-28-en-14-yl]oxidanesulfonic acid

C40H74O14S3 (874.4240464)


   

[(2s,14s,16r,28e)-30-oxo-16-(sulfooxy)-2-[(2s,9z)-2-(sulfooxy)undec-9-en-1-yl]-1-oxacyclotriacont-28-en-14-yl]oxidanesulfonic acid

[(2s,14s,16r,28e)-30-oxo-16-(sulfooxy)-2-[(2s,9z)-2-(sulfooxy)undec-9-en-1-yl]-1-oxacyclotriacont-28-en-14-yl]oxidanesulfonic acid

C40H74O14S3 (874.4240464)


   

4-{2,3a-dihydroxy-7-[(3-hydroxy-4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl}-5h-furan-2-one

4-{2,3a-dihydroxy-7-[(3-hydroxy-4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl}-5h-furan-2-one

C42H66O19 (874.4198086000001)


   

4-[(2s,3as,3br,5ar,7s,9as,9bs,11ar)-7-{[(2r,3r,4r,5s,6r)-5-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-2,3a-dihydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

4-[(2s,3as,3br,5ar,7s,9as,9bs,11ar)-7-{[(2r,3r,4r,5s,6r)-5-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-2,3a-dihydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one

C42H66O19 (874.4198086000001)


   

[(28e)-30-oxo-16-(sulfooxy)-2-[(9e)-2-(sulfooxy)undec-9-en-1-yl]-1-oxacyclotriacont-28-en-14-yl]oxidanesulfonic acid

[(28e)-30-oxo-16-(sulfooxy)-2-[(9e)-2-(sulfooxy)undec-9-en-1-yl]-1-oxacyclotriacont-28-en-14-yl]oxidanesulfonic acid

C40H74O14S3 (874.4240464)


   

10-{[4,5-dihydroxy-6-methyl-3-(sulfooxy)oxan-2-yl]oxy}-1,2,6b,9,9,12a-hexamethyl-4a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-6a-carboxylic acid

10-{[4,5-dihydroxy-6-methyl-3-(sulfooxy)oxan-2-yl]oxy}-1,2,6b,9,9,12a-hexamethyl-4a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-6a-carboxylic acid

C42H66O17S (874.4020506000002)


   

(1s,2r,4as,6ar,6br,8ar,10s,12ar,12br,14bs)-10-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-methyl-3-(sulfooxy)oxan-2-yl]oxy}-1,2,6b,9,9,12a-hexamethyl-4a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-6a-carboxylic acid

(1s,2r,4as,6ar,6br,8ar,10s,12ar,12br,14bs)-10-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-methyl-3-(sulfooxy)oxan-2-yl]oxy}-1,2,6b,9,9,12a-hexamethyl-4a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-6a-carboxylic acid

C42H66O17S (874.4020506000002)


   

(7z,11z)-17-{[3,4-dihydroxy-5-(4-hydroxy-2-methoxy-6-methylbenzoyloxy)-6-methyloxan-2-yl]oxy}-23-hydroxy-3,6,8,12,14,19,22-heptamethyl-25,27-dioxo-26-oxapentacyclo[22.2.1.0¹,⁶.0¹³,²².0¹⁶,²¹]heptacosa-4,7,11,19,23-pentaene-4-carboxylic acid

(7z,11z)-17-{[3,4-dihydroxy-5-(4-hydroxy-2-methoxy-6-methylbenzoyloxy)-6-methyloxan-2-yl]oxy}-23-hydroxy-3,6,8,12,14,19,22-heptamethyl-25,27-dioxo-26-oxapentacyclo[22.2.1.0¹,⁶.0¹³,²².0¹⁶,²¹]heptacosa-4,7,11,19,23-pentaene-4-carboxylic acid

C49H62O14 (874.4139352)


   

(2s,10r,27r,44s)-51-hydroxy-13,13,20,20,34,34,41,41-octamethyl-5,49,52-trioxo-21,33-dioxa-3,6,15,39,48,50-hexaazapentadecacyclo[42.5.2.1³,¹⁰.0¹,⁴².0²,²⁸.0⁴,¹².0⁴,²⁷.0⁶,¹⁰.0¹⁴,²⁶.0¹⁶,²⁵.0¹⁷,²².0²⁸,⁴⁰.0²⁹,³⁸.0³²,³⁷.0⁴⁴,⁴⁸]dopentaconta-14(26),16,18,22,24,29(38),30,32(37),35,39,50-undecaen-39-ium-39-olate

(2s,10r,27r,44s)-51-hydroxy-13,13,20,20,34,34,41,41-octamethyl-5,49,52-trioxo-21,33-dioxa-3,6,15,39,48,50-hexaazapentadecacyclo[42.5.2.1³,¹⁰.0¹,⁴².0²,²⁸.0⁴,¹².0⁴,²⁷.0⁶,¹⁰.0¹⁴,²⁶.0¹⁶,²⁵.0¹⁷,²².0²⁸,⁴⁰.0²⁹,³⁸.0³²,³⁷.0⁴⁴,⁴⁸]dopentaconta-14(26),16,18,22,24,29(38),30,32(37),35,39,50-undecaen-39-ium-39-olate

C52H54N6O7 (874.4053774000001)


   

(2s)-3-{[(1s,2r,6z,8s,9s,10s,12r,16s)-9-{[(2s,3r,4s)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-3-ethyl-2-({[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-8,10,12-trimethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadec-6-en-15-yl]sulfanyl}-2-[(1-hydroxyethylidene)amino]propanoic acid

(2s)-3-{[(1s,2r,6z,8s,9s,10s,12r,16s)-9-{[(2s,3r,4s)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-3-ethyl-2-({[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-8,10,12-trimethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadec-6-en-15-yl]sulfanyl}-2-[(1-hydroxyethylidene)amino]propanoic acid

C42H70N2O15S (874.4496670000001)